Prevalence of Congenital Heart Disease Amongst Schoolchildren in Southwest China

Objective: To investigate the prevalence and risk factors of congenital heart disease inYunnan, China which has diverse ethnic groups. Methods: This cross-sectional studyenrolled 244,023 children from 2010 to 2015. To diagnose CHD, a conventional physicalexamination was used to screen suspicious cases, which were further confirmed byechocardiography. Results: A total of 1695 children were diagnosed with CHD. Theestimated prevalence was 6.94%. Atrial septal defects were the most common cardiacabnormalities. A higher prevalence of CHD was observed with preterm birth, low birthweight, maternal age ≥35 years, and high-altitude regions. The prevalence also showeddifferences between diverse ethnic groups. Conclusion: The prevalence of CHD in Chinamay have ethnic differences.

Human umbilical cord-derived mesenchymal stem cells in the treatment of myocardial infarction: existing problems, effects and prospects / 中国组织工程研究

BACKGROUND: Human umbilical cord-derived mesenchymal stem cells, because of convenient acquisition, will not bring pain and adverse effects to the fetus and their parturient. The success rate of culture is high. It has good application prospects in the treatment of myocardial infarction. OBJECTIVE: To review the new progress of human umbilical cord-derived mesenchymal stem cells transplantation in the treatment of myocardial infarction. METHODS: A computer-based online search of PubMed and Wanfang databases was performed to retrieve the related articles published from 1991 to 2017. We reviewed the initial data and the quotations from each document. Finally, we included randomized controlled animal experiments or clinical studies concerning human umbilical cord-derived mesenchymal stem cells for treatment of myocardial infarction. RESULTS AND CONCLUSION: Human umbilical cord-derived mesenchymal stem cells will become a new alternative source of cells in the treatment of myocardial infarction, with extremely broad prospects. However, there is no mature conclusion about the convenient route, optimal number of transplanted cells, optimal timing, differentiation, homing and evaluation after transplantation, which limits the clinical application of these cells.